Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Marshall Edwards Announces Name Change to MEI Pharma ("MEIP") New Name and Ticker Symbol Effective Monday, July 2, 2012 PR Newswire SAN DIEGO, June 28, 2012 SAN DIEGO, June 28, 2012 /PRNewswire/...
Marshall Edwards Presents Results From Clinical Trial Of Lead Oncology Drug Candidate ME-143 Data Presented at the American Society of Clinical Oncology Annual Meeting PR Newswire SAN DIEGO, June...
Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344 PR Newswire SAN DIEGO, May 29, 2012 SAN DIEGO, May 29, 2012 /PRNewswire/...
Marshall Edwards Completes Rights Offering To Stockholders PR Newswire SAN DIEGO, May 14, 2012 SAN DIEGO, May 14, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company...
Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering PR Newswire SAN DIEGO, May 8, 2012 SAN DIEGO, May 8, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq:...
Marshall Edwards Issued New Patent For Use Of Lead Drug Candidate ME-143 In Treating Cancer Company Also Announces Two Japanese Patents Covering Lead Drug Candidates PR Newswire SAN DIEGO, April...
Marshall Edwards Receives FDA Approval of Investigational New Drug Application for Clinical Testing of Oncology Drug Candidate ME-344 PR Newswire SAN DIEGO, April 10, 2012 SAN DIEGO, April 10...
Marshall Edwards Announces Data from Clinical Trial of ME-143 Selected for Presentation at ASCO Annual Meeting PR Newswire SAN DIEGO, April 3, 2012 SAN DIEGO, April 3, 2012 /PRNewswire/...
Marshall Edwards CEO to Present at Needham Healthcare Conference Live Webcast from New York on Wednesday, April 4 PR Newswire SAN DIEGO, March 28, 2012 SAN DIEGO, March 28, 2012 /PRNewswire/...
Marshall Edwards Receives Notice of Effectiveness for Rights Offering to Stockholders PR Newswire SAN DIEGO, March 27, 2012 SAN DIEGO, March 27, 2012 /PRNewswire/ -- Marshall Edwards, Inc...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
